JP2023554087A5 - - Google Patents
Info
- Publication number
- JP2023554087A5 JP2023554087A5 JP2023537098A JP2023537098A JP2023554087A5 JP 2023554087 A5 JP2023554087 A5 JP 2023554087A5 JP 2023537098 A JP2023537098 A JP 2023537098A JP 2023537098 A JP2023537098 A JP 2023537098A JP 2023554087 A5 JP2023554087 A5 JP 2023554087A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- amino acid
- seq
- acid sequence
- sequence described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020904684 | 2020-12-16 | ||
| AU2020904684A AU2020904684A0 (en) | 2020-12-16 | Protein formulations and uses thereof | |
| PCT/AU2021/050736 WO2022126173A1 (en) | 2020-12-16 | 2021-07-09 | Protein formulations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554087A JP2023554087A (ja) | 2023-12-26 |
| JP2023554087A5 true JP2023554087A5 (https=) | 2024-07-18 |
Family
ID=82059564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537098A Pending JP2023554087A (ja) | 2020-12-16 | 2021-07-09 | タンパク質製剤及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240002517A1 (https=) |
| EP (1) | EP4262750A4 (https=) |
| JP (1) | JP2023554087A (https=) |
| KR (1) | KR20230122034A (https=) |
| CN (1) | CN117042755A (https=) |
| AU (1) | AU2021399879A1 (https=) |
| CA (1) | CA3198770A1 (https=) |
| WO (1) | WO2022126173A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12583929B2 (en) * | 2020-06-04 | 2026-03-24 | CSL Innovation Pty Ltd | Method of treating acute respiratory distress syndrome |
| JP2024518536A (ja) * | 2021-05-12 | 2024-05-01 | アナプティスバイオ インコーポレイティッド | 抗体組成物 |
| US20250042984A1 (en) * | 2021-12-20 | 2025-02-06 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
| IL325176A (en) * | 2023-07-05 | 2026-02-01 | CSL Innovation Pty Ltd | Methods for treating or preventing a complication of sickle cell disease |
| WO2025217676A1 (en) * | 2024-04-15 | 2025-10-23 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
| WO2025217678A1 (en) * | 2024-04-15 | 2025-10-23 | CSL Innovation Pty Ltd | Methods of treating or delaying progression or hindering development of a neutrophil-associated condition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2718326B1 (en) * | 2011-06-13 | 2020-08-19 | CSL Limited | Antibodies against g-csfr and uses thereof |
| DK4364724T3 (da) * | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3876990A4 (en) * | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| BR112021010920A2 (pt) * | 2018-12-04 | 2021-08-31 | CSL Innovation Pty Ltd | Método de tratamento de condições neutrofílicas |
-
2021
- 2021-07-09 JP JP2023537098A patent/JP2023554087A/ja active Pending
- 2021-07-09 CA CA3198770A patent/CA3198770A1/en active Pending
- 2021-07-09 WO PCT/AU2021/050736 patent/WO2022126173A1/en not_active Ceased
- 2021-07-09 CN CN202180085281.3A patent/CN117042755A/zh active Pending
- 2021-07-09 KR KR1020237021374A patent/KR20230122034A/ko active Pending
- 2021-07-09 US US18/037,397 patent/US20240002517A1/en active Pending
- 2021-07-09 EP EP21904642.2A patent/EP4262750A4/en active Pending
- 2021-07-09 AU AU2021399879A patent/AU2021399879A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554087A5 (https=) | ||
| KR102397713B1 (ko) | 안정한 액체 약제학적 제제 | |
| CA2734919C (en) | Lyophilized formulations of engineered anti-il-23p19 antibodies | |
| KR101367743B1 (ko) | 약제학적 항-종양 괴사 인자-α 항체 제제 | |
| TWI480064B (zh) | 人類抗－ＴＮＦα抗體之穩定高蛋白質濃度調配物 | |
| US20170360929A1 (en) | Stable aqueous antibody formulation for anti tnf alpha antibodies | |
| JP2021512881A5 (https=) | ||
| KR102385802B1 (ko) | Gm-csf 중화 화합물을 포함하는 액체 제제 | |
| KR102106914B1 (ko) | Gm-csf를 중화하는 화합물을 포함하는 액체 제제 | |
| AU2015332151A1 (en) | Anti-IL-7R antibody compositions | |
| EP4151233A1 (en) | Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof | |
| WO2022135395A1 (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| KR20250077436A (ko) | 안정한 항체 조성물 | |
| JP2021523881A5 (https=) | ||
| CN119255788A (zh) | 降黏度赋形剂组合物和包含其的低黏度高浓缩蛋白质制剂 | |
| RU2024127270A (ru) | Препараты, содержащие биспецифическое антитело против claudin18.2/cd3, способ их получения и применение | |
| HK40109650A (zh) | 制剂 | |
| KR20250106231A (ko) | 안정한 약제학적 제제 | |
| AU2013204238A1 (en) | Stable high protein concentration formulations of human anti-TNF-alpha-antibodies |